Metomidate

Metomidate is a non-barbiturate imidazole that was discovered by Janssen Pharmaceutica in 1965[1] and under the names (Hypnodil, Nokemyl) is sold as a sedative-hypnotic drug used in Europe to treat humans and for veterinary purposes.[2]

Metomidate

Clinical data
ATCvet code	QN05CM94 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
CAS Number	5377-20-8
PubChem CID	21474
ChemSpider	20182
UNII	Z18ZYL8Y51
ChEMBL	ChEMBL494039
CompTox Dashboard (EPA)	DTXSID1048411
ECHA InfoCard	100.023.971
Chemical and physical data
Formula	C13H14N2O2
Molar mass	230.267 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(OC)c1cncn1C(c2ccccc2)C
InChI InChI=1S/C13H14N2O2/c1-10(11-6-4-3-5-7-11)15-9-14-8-12(15)13(16)17-2/h3-10H,1-2H3 Key:FHFZEKYDSVTYLL-UHFFFAOYSA-N
(what is this?)  (verify)

¹¹C-labelled metomidate (11C-metomidate), may be used with positron emission tomography (PET). For instance, to detect tumors of adrenocortical origin.[3][4]

See also

• Etomidate
• Propoxate

References

1. BE Patent 662474
2. Index nominum 2000: international drug directory. Taylor & Francis US. 2000. p. 683. ISBN 978-3-88763-075-1. Retrieved 27 October 2011.
3. Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B (March 2003). "11C-metomidate PET imaging of adrenocortical cancer". European Journal of Nuclear Medicine and Molecular Imaging. 30 (3): 403–10. doi:10.1007/s00259-002-1025-9. PMID 12634969. S2CID 23744095.
4. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Långsjö J, et al. (June 2004). "Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG". Journal of Nuclear Medicine. 45 (6): 972–9. PMID 15181132.